Contents

Highlights of This Issue 4303

SPECIAL FEATURES

Editorial

4305 Food and Oral Antineoplastics: More Than Meets the Eye
Rajul K. Jain, Satjit S. Brar, and Lawrence J. Lesko
See article p. 4446

CCR Translations

4308 Personalized Tamoxifen: A Step Closer but Miles To Go
Aditya Bardia and Vered Stearns
See article p. 4468

4311 Arsenic Trioxide and the Phosphoinositide 3-Kinase/Akt Pathway in Chronic Lymphocytic Leukemia
Dennis J. Goussetis and Leonidas C. Platanias
See article p. 4382

CCR New Strategies

4313 New Strategies in Pancreatic Cancer: Emerging Epidemiologic and Therapeutic Concepts
Donghui Li and James L. Abbruzzese

Molecular Pathways

4319 Overcoming Persistent Dependency on Androgen Signaling after Progression to Castration-Resistant Prostate Cancer
Masuo Yamaoka, Takahito Harai, and Masami Kusaka

4325 PI(3)King Apart PTEN's Role in Cancer
Siyuan Zhang and Dihua Yu

Report from the FDA

4331 U.S. Food and Drug Administration Approval: Ofatumumab for the Treatment of Patients with Chronic Lymphocytic Leukemia Refractory to Fludarabine and Alemtuzumab
Steven J. Lemery, Jenny Zhang, Mark D. Rothmann, Jun Yang, Justin Earp, Hong Zhao, Andrew McDougal, Anne Pilaro, Raymond Chiang, Joseph E. Gootenberg, Patricia Keegan, and Richard Pazdur

HUMAN CANCER BIOLOGY

Transcriptional Profiling of Polycythemia Vera Identifies Gene Expression Patterns Both Dependent and Independent from the Action of JAK2V617F

Meta-analysis of Neuroblastomas Reveals a Skewed ALK Mutation Spectrum in Tumors with MYCN Amplification
Sara De Brouwer, Katelyn De Preter, Candy Kumps, Piotr Zabrocki, Michael Porcu, Ellen M. Westerhout, Arjan Lakeman, Jo Vandesompele, Jasmien Hoebeck, Tom Van Maerken, Anne De Paepe, Genevieve Laureys, Johannes H. Schulte, Alexander Schramm, Caroline Van Den Broecke, Joëlle Vermeulen, Nadine Van Roy, Klaus Beiske, Marleen Renard, Rosa Noguera, Olivier Delattre, Isabelle Janoueix-Lerosey, Per Kogner, Tommy Martinsson, Akira Nakagawara, Miki Ohira, Huib Caron, Angelika Egger, Jan Cools, Rogier Versteeg, and Frank Speleman

Upregulation of SOX9 in Lung Adenocarcinoma and Its Involvement in the Regulation of Cell Growth and Tumorigenicity
### Cancer Therapy: Preclinical

<table>
<thead>
<tr>
<th>Page</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>4382</td>
<td>Induction of B-Chronic Lymphocytic Leukemia Cell Apoptosis by Arsenic Trioxide Involves Suppression of the Phosphoinositide 3-Kinase/Akt Survival Pathway via c-jun-NH₂ Terminal Kinase Activation and PTEN Upregulation</td>
<td>Javier Redondo-Muñoz, Elizabeth Escobar-Díaz, Mercedes Hernández del Cerro, Atanasio Pandiella, María José Terol, José A. García-Marco, and Angeles García-Pardo</td>
</tr>
<tr>
<td>4392</td>
<td>Actinomycin D Decreases Mcl-1 Expression and Acts Synergistically with ABT-737 against Small Cell Lung Cancer Cell Lines</td>
<td>Haishan Xu and Geoffrey W. Krystal</td>
</tr>
</tbody>
</table>

### Cancer Therapy: Clinical

<table>
<thead>
<tr>
<th>Page</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>4411</td>
<td>Notch1 Expression Predicts an Unfavorable Prognosis and Serves as a Therapeutic Target of Patients with Neuroblastoma</td>
<td>Hsiu-Hao Chang, Hsinyu Lee, Ming-Kuan Hu, Po-Nien Tsao, Hsueh-Fen Juan, Min-Chuan Huang, Yu-Yin Shih, Bo-Jeng Wang, Yung-Ming Jeng, Christina Ling Chang, Shiu-Feng Huang, Yeou-Guang Tsay, Fon-Jou Hsieh, Kai-Hsin Lin, Wen-Ming Hsu, and Yung-Feng Liao</td>
</tr>
<tr>
<td>4434</td>
<td>Preclinical and Clinical Evidence that Deoxy-2-[¹⁸F]fluoro-D-glucose Positron Emission Tomography with Computed Tomography Is a Reliable Tool for the Detection of Early Molecular Responses to Erlotinib in Head and Neck Cancer</td>
<td>Sébastien Vergez, Jean-Pierre Delord, Fabienne Thomas, Philippe Rochaix, Olivier Caselles, Thomas Filleron, Séverine Brillouet, Pierre Canal, Frédéric Courbon, and Ben C. Allal</td>
</tr>
</tbody>
</table>

### Imaging, Diagnosis, Prognosis

<table>
<thead>
<tr>
<th>Page</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>4452</td>
<td>Histopathologic and Immunohistochemical Characterization of Rash to Human Epidermal Growth Factor Receptor 1 (HER1) and HER1/2 Inhibitors in Cancer Patients</td>
<td>Beatrice Nardone, Kimberly Nicholson, Marianna Newman, Joan Gutirat, Pedram Gerami, Nicholas Talarico, Ximing J. Yang, Alfred Rademaker, Dennis P. West, and Mario E. Lacouture</td>
</tr>
</tbody>
</table>
This is an original study providing, from preclinical models to patients, a reliable proof of 18FDG-PET/CT efficiency as a surrogate marker for the early evaluation of EGFR-TKI (erlotinib) efficacy that may improve diagnostic accuracy of molecular effect (ERK1/2). The image represents a facial sagittal section of an 18FDG-PET/CT of a patient with an oropharyngeal head and neck squamous cell carcinoma. It reveals a tumor 18FDG uptake before patient exposure to erlotinib. For further details, please see the article by Vergez and colleagues on page 4434 of this issue.